查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1808837

基于 EV 的液体活检市场，按生物标记类型、按样本类型、按应用、按最终用户、按国家和地区划分 - 2025 年至 2032 年全球行业分析、市场规模、市场份额及预测

EV-Based Liquid Biopsy Market, By Biomarker Type, By Sample Type, By Application, By End-user, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 365 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2024 年基于 EV 的液体活检市场规模价值为 3.5523 亿美元，2025 年至 2032 年的复合年增长率为 19.5%。

基于胞外囊泡的液体活检市场专注于利用细胞外载体 (EV) 作为非侵入性诊断工具。 EV 是细胞自然释放到体液（例如血液、唾液和尿液）中的奈米级颗粒。这些囊泡携带生物讯息，例如 RNA、DNA、蛋白质和脂质，这些讯息反映了其来源细胞的状态。这使得它们在检测和监测疾病（尤其是癌症）方面具有重要价值。与传统活检不同，基于 EV 的液体活检可以减轻患者的不适感，并能够即时追踪病情进展。它们也有利于检测那些使用常规方法难以接近或监测的肿瘤。

人们对精准医疗、早期疾病检测和微创诊断的兴趣日益浓厚，推动了这项技术的普及。此外，与其他生物标记物相比，EVs 在血液循环中更稳定，从而提高了其可靠性。由于持续的研究、分离技术的改进以及更广泛的临床应用，EVs 市场正在不断扩大。儘管存在一些挑战，包括缺乏标准化和监管明确性，但基于 EVs 的液体活检正逐渐成为现代诊断领域具有相当前景的工具。

基于电动车的液体活检市场-市场动态

医院内感染控制规程的不断增加推动了对针头销毁器的需求。

基于细胞外囊泡 (EV) 的液体活检市场的一个关键利基驱动因素是，使用细胞外囊泡 (EV) 生物标记进行非侵入性癌症监测的需求日益增长。传统的癌症诊断通常依赖侵入性组织活检，这种活检可能带来疼痛、风险高，而且并非总是可行，尤其是位于难以触及部位的肿瘤。癌细胞释放到体液中的 EV 携带着反映肿瘤状态的遗传和蛋白质组讯息。这使得临床医生能够透过血液等简单的体液样本来追踪癌症进展、治疗反应或復发情况。

连续采样技术能够实现即时监测，无需患者反覆接受侵入性操作。此外，EVs 在血液循环中比游离 DNA 等其他生物标记物更稳定，从而提高了结果的可靠性。随着肿瘤学朝向个人化和精准化方向发展，基于 EVs 的活检正成为客製化治疗方案的宝贵工具。在因患者健康状况或肿瘤位置而无法进行组织活检的情况下，其作用尤其重要。日益增长的临床需求持续推动 EVs 诊断技术的创新和投资。

基于电动车的液体活检市场—关键洞察

根据我们的研究分析师的分析，预计全球市场在预测期内（2025-2032 年）的年复合成长率约为 19.5%。

根据生物标记类型细分，预计 microRNA（miRNA）和信使 RNA（mRNA）将在 2024 年占据最大市场份额

根据样本类型细分，血液是 2024 年的主要样本类型

根据应用细分，癌症诊断是 2024 年领先的应用

从地区来看，北美是 2024 年最大的收入来源

基于 EV 的液体活检市场-細項分析：

全球基于 EV 的液体活检市场根据生物标誌物类型、样本类型、应用、最终用户和地区进行细分。

根据生物标记类型，市场可分为四类：蛋白质、RNA（miRNA、mRNA 等）、DNA、脂质、其他。在基于 EV 的液体活检市场中，RNA（包括 microRNA (miRNA) 和信使 RNA (mRNA)）占据主导地位。这种突出地位源自于 RNA 在反映起源细胞（尤其是癌细胞）遗传活动方面所扮演的关键角色。 EV 携带稳定的 RNA 分子，为基因表现模式提供宝贵的见解，从而实现早期疾病的检测和监测。

与其他生物分子相比，RNA生物标记具有较高的特异性和敏感性，这对于准确的诊断和预后至关重要。尤其是miRNA，它调节各种细胞过程，并与肿瘤进展相关，使其成为液体活检的有力指标。此外，RNA定序和分析技术的进步提高了可靠地检测和定量EV相关RNA的能力。个人化医疗日益受到关注，这进一步支持了RNA生物标记的应用，因为它们有助于根据分子谱量身定制治疗方案。儘管从EV中分离纯RNA面临挑战，但正在进行的研究正在克服这些障碍，巩固了RNA作为该市场关键驱动力的地位。

根据应用，市场分为五类：癌症诊断、传染病、神经系统疾病、心血管疾病和其他。癌症诊断是EV液体活检市场中最主要的样本类型细分市场。这种主导地位源于对早期、准确、微创的癌症检测和监测方法的迫切需求。肿瘤细胞释放的细胞外囊泡携带蛋白质、RNA和DNA等分子特征，可提供有关肿瘤存在、进展和治疗反应的即时资讯。与传统的组织活检不同，EV液体活检可以透过简单的血液或体液样本进行持续监测，从而减少患者不适并实现更早的干预。

全球癌症负担的不断上升以及对个人化医疗的日益重视，进一步推动了基于EV的诊断技术在肿瘤学中的应用。此外，这些液体活检有助于检测那些难以透过常规方法接近或监测的肿瘤。研究和临床试验持续验证EV生物标记在癌症检测中的有效性，这使得此样本类型成为市场的主要成长动力。虽然传染病和神经系统疾病等其他样本类型正在兴起，但癌症诊断目前仍是基于EV的液体活检开发和商业化的重点。

电动汽车液体活检市场—地理洞察

在北美，得益于先进的医疗基础设施和创新诊断技术的早期应用，基于囊泡的液体活检市场发展势头强劲。该地区受益于由学术机构、生物技术公司和专注于癌症诊断的政府资助计画支持的强大研究生态系统。医疗保健专业人士对细胞外囊泡在非侵入性疾病检测和监测中的临床价值的认识日益加深。完善的监管框架和正在进行的临床试验促进了基于囊泡的检测与临床实践的整合。

美国在基于囊泡的液体活检市场中处于领先地位，这得益于其先进的医疗基础设施和对早期癌症检测的高度重视。美国强大的科研生态系统，涵盖领先的学术机构和生物终端用户公司，促进了诊断技术的持续创新。临床医生和患者对非侵入性诊断方法的日益青睐，加速了基于囊泡的液体活检的应用，该技术可以即时洞察病情进展和治疗反应。美国食品药物管理局 (FDA) 在监管这些新兴技术方面发挥关键作用，确保其符合安全性和有效性标准。然而，挑战依然存在，包括需要製定囊泡分离和分析的标准化方案。

基于 EV 的液体活检市场-竞争格局：

基于囊泡的液体活检市场的竞争格局由众多成熟的生物终端用户公司和专注于细胞外囊泡技术的创新新创公司共同塑造。 Exosome Diagnostics、赛默飞世尔科技和Qiagen等公司是产业翘楚，它们利用自身强大的研发实力和全球影响力，推动基于囊泡的诊断技术发展。 Bio-Techne Corporation和NanoView Biosciences也透过囊泡检测和表征技术创新取得了重大进展。同时，System Biosciences (SBI)、美天旎生物技术公司和AMSBIO也正在提供专业的囊泡分离和分析试剂盒。

Exosomics SpA、Codiak BioSciences 和 VivaZome Therapeutics 等新兴公司正在透过开发基于 EV 的新型平台（专门针对肿瘤学和个人化医疗）加剧竞争。市场瞬息万变，策略合作、研究伙伴关係和临床验证在塑造竞争地位方面发挥关键作用。随着监管途径日益清晰，这些公司可望扩大在临床领域的布局。

最新动态：

2024年10月，QIAGEN扩展了其自动化液体活检产品组合，以增强其在肿瘤学、产前护理和器官移植领域的应用。全新升级的ccfDNA试剂盒，包含适用于EZ1和2仪器的尿液检测方案，旨在改善癌症研究的液体活检工作流程。 QIAsymphony DSP循环DNA和Maxi试剂盒可为下游应用提供高品质的cfDNA。

目录

第 1 章：基于 EV 的液体活检市场概述

  • 研究范围
  • 市场估计年限

第二章：执行摘要

  • 市场片段
    • EV 液体活检市场片段（按生物标记类型）
    • EV 液体活检市场（按样本类型）
    • 基于 EV 的液体活检市场片段（按应用）
    • EV 液体活检市场片段（按最终用户）
    • 电动汽车液体活检市场（按国家/地区）
    • 电动汽车液体活检市场（按地区）
  • 竞争洞察

第三章：基于 EV 的液体活检关键市场趋势

  • 基于电动车的液体活检市场驱动因素
    • 市场驱动因素的影响分析
  • 基于EV的液体活检市场限制
    • 市场限制的影响分析
  • 基于EV的液体切片市场机会
  • 基于EV的液体切片市场未来趋势

第四章：基于电动车的液体活检产业研究

  • PEST分析
  • 波特五力分析
  • 成长前景图
  • 规范架构分析

第五章：基于电动车的液体活检市场：地缘政治紧张局势升级的影响

  • COVID-19 疫情的影响
  • 俄乌战争的影响
  • 中东衝突的影响

第六章：基于 EV 的液体活检市场格局

  • 2024年EV液体切片市场份额分析
  • 按主要製造商分類的细分数据
    • 成熟玩家分析
    • 新兴企业分析

第 7 章：基于 EV 的液体活检市场 - 按生物标记类型

  • 概述
    • 按生物标誌物类型分類的细分市场份额分析
    • 蛋白质
    • RNA（miRNA、mRNA等）
    • 脱氧核糖核酸
    • 脂质
    • 其他的

第 8 章：基于 EV 的液体活检市场 - 按样本类型

  • 概述
    • 依样本类型进行细分份额分析
    • 血
    • 尿
    • 唾液
    • 脑脊髓液
    • 其他的

第 9 章：基于 EV 的液体活检市场 - 按应用

  • 概述
    • 按应用细分市场占有率分析
    • 癌症诊断
    • 传染病
    • 神经系统疾病
    • 心血管疾病
    • 其他的

第 10 章：基于 EV 的液体活检市场 - 按最终用户

  • 概述
    • 依样本类型进行细分份额分析
    • 医院和诊所
    • 研究机构
    • 诊断实验室
    • 生物製药公司
    • 其他的

第 11 章：基于 EV 的液体活检市场 - 按地区划分

  • 介绍
    • 按地区分類的细分市场占有率分析
  • 北美洲
    • 概述
    • 北美EV液体切片主要製造商
    • 北美市场规模及预测（按国家/地区）
    • 北美市场规模及预测（依生物标记类型）
    • 北美市场规模和预测（按样本类型）
    • 北美市场规模和预测（按应用）
    • 北美市场规模及预测（按最终用户）
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • 欧洲EV液体活检主要製造商
    • 欧洲市场规模及预测（按国家/地区）
    • 欧洲市场规模及预测（依生物标记类型）
    • 欧洲市场规模及预测（依样本类型）
    • 欧洲市场规模和预测，按应用
    • 欧洲市场规模及预测（按最终用户）
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 荷兰
    • 瑞典
    • 俄罗斯
    • 波兰
    • 欧洲其他地区
  • 亚太地区 (APAC)
    • 概述
    • 亚太地区基于EV的液体活检主要製造商
    • 亚太地区市场规模及预测（依国家）
    • 亚太地区市场规模及预测（依生物标记类型）
    • 亚太地区市场规模及预测（依样本类型）
    • 亚太地区市场规模及预测（按应用）
    • 亚太地区市场规模及预测（依最终用户）
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲
    • 印尼
    • 泰国
    • 菲律宾
    • 亚太地区其他地区
  • 拉丁美洲（LATAM）
    • 概述
    • 拉丁美洲基于EV的液体活检关键製造商
    • 拉丁美洲市场规模及预测（按国家/地区）
    • 拉丁美洲市场规模及预测（依生物标记类型）
    • 拉丁美洲市场规模及预测（依样本类型）
    • 拉丁美洲市场规模及预测（按应用）
    • 拉丁美洲市场规模及预测（按最终用户）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 拉丁美洲其他地区
  • 中东和非洲（MEA）
    • 概述
    • 中东和非洲基于 EV 的液体活检关键製造商
    • MEA 市场规模及预测（依国家/地区）
    • MEA 市场规模及预测（依生物标记类型）
    • MEA 市场规模及预测（依样品类型）
    • MEA 市场规模及预测（按应用）
    • MEA 市场规模及预测（依最终用户）
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • MEA 其余地区

第 12 章：关键供应商分析-基于 EV 的液体活检产业

  • 竞争仪錶板
    • Competitive Benchmarking
    • Competitive Positioning
  • 公司简介
    • Exosome Diagnostics
    • Bio-Techne Corporation
    • Thermo Fisher Scientific
    • NanoView Biosciences
    • System Biosciences (SBI)
    • Qiagen
    • Norgen Biotek Corp.
    • BioVision Inc.
    • Miltenyi Biotec
    • Creative Biolabs
    • AMSBIO
    • Exosomics SpA
    • NX Pharmagen
    • VivaZome Therapeutics
    • Aethlon Medical
    • Evox Therapeutics
    • Capricor Therapeutics
    • Codiak BioSciences
    • Anjarium Biosciences
    • HansaBioMed Life Sciences

第 13 章：360 度分析师视角

第 14 章：附录

  • 研究方法
  • 参考
  • 缩写
  • 免责声明
  • 联络我们
简介目录
Product Code: ANV5501

EV-Based Liquid Biopsy Market size was valued at US$ 355.23 Million in 2024, expanding at a CAGR of 19.5% from 2025 to 2032.

The EV-based liquid biopsy market focuses on the use of extracellular vehicles (EVs) as a non-invasive diagnostic tool. EVs are nano-sized particles naturally released by cells into bodily fluids such as blood, saliva, and urine. These vesicles carry biological information, like RNA, DNA, proteins, and lipids, that reflects the state of their originating cells. This makes them valuable for detecting and monitoring diseases, especially cancers. Unlike traditional biopsies, EV-based liquid biopsies reduce patient discomfort and enable real-time tracking of disease progression. They are also advantageous for detecting tumors that are difficult to access or monitor using conventional methods.

Growing interest in precision medicine, early disease detection, and less invasive diagnostics is driving the adoption of this technology. Additionally, EVs are more stable in circulation compared to other biomarkers, which enhances their reliability. The market is expanding due to ongoing research, improved isolation techniques, and broader clinical applications. Despite some challenges, including a lack of standardization and regulatory clarity, EV-based liquid biopsy is emerging as a promising tool in modern diagnostics.

EV-Based Liquid Biopsy Market- Market Dynamics

Rising hospital-acquired infection control protocols drive demand for needle destroyers.

A key niche driver for the EV-based liquid biopsy market is the growing demand for non-invasive cancer monitoring using extracellular vesicle (EV) biomarkers. Traditional cancer diagnostics often rely on invasive tissue biopsies, which can be painful, risky, and not always feasible, especially for tumors in inaccessible locations. EVs, released by cancer cells into body fluids, carry genetic and proteomic information that mirrors the tumor's state. This enables clinicians to track cancer progression, therapeutic response, or recurrence with simple fluid samples like blood.

The ability to perform serial sampling offers real-time monitoring without subjecting patients to repeated invasive procedures. Additionally, EVs are more stable in circulation than other biomarkers like cell-free DNA, improving result reliability. As oncology shifts toward personalized and precision-based approaches, EV-based biopsies are becoming a valuable tool for tailoring treatments. Their role is particularly significant in cases where tissue biopsy is not possible due to the patient's health or tumor location. This rising clinical demand continues to propel innovation and investment in EV-based diagnostics.

EV-Based Liquid Biopsy Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 19.5% over the forecast period (2025-2032)

Based on Biomarker Type segmentation, microRNA (miRNA) and messenger RNA (mRNA), were predicted to show maximum market share in the year 2024

Based on Sample Type segmentation, Blood was the leading Sample Type in 2024

Based on Application segmentation, Cancer diagnostics was the leading Application in 2024

Based on region, North America was the leading revenue generator in 2024

EV-Based Liquid Biopsy Market- Segmentation Analysis:

The Global EV-Based Liquid Biopsy Market is segmented based on Biomarker Type, Sample Type, Application, End-user, and Region.

The market is divided into four categories based on Biomarker Type. Proteins, RNA (miRNA, mRNA, etc.), DNA, Lipids, Others. Among the biomarker types in the EV-based liquid biopsy market, RNA, including microRNA (miRNA) and messenger RNA (mRNA), emerges as the most dominant segment. This prominence is due to the critical role RNA plays in reflecting the genetic activity of originating cells, especially cancer cells. EVs carry stable RNA molecules that provide valuable insights into gene expression patterns, enabling early disease detection and monitoring.

Compared to other biomolecules, RNA biomarkers offer high specificity and sensitivity, which are essential for accurate diagnosis and prognosis. miRNAs, in particular, regulate various cellular processes and have been linked to tumor progression, making them powerful indicators in liquid biopsies. Additionally, advances in RNA sequencing and analysis technologies have improved the ability to detect and quantify EV-associated RNAs reliably. The growing focus on personalized medicine further supports the use of RNA biomarkers, as they help tailor treatments based on molecular profiles. Despite challenges in isolating pure RNA from EVs, ongoing research is overcoming these obstacles, cementing RNA's position as a key driver in this market.

The market is divided into five categories based on Application: Cancer Diagnostics, Infectious Diseases, Neurological Disorders, Cardiovascular Diseases, and Others. Cancer diagnostics is the most dominant Sample Type segment in the EV-based liquid biopsy market. This dominance stems from the critical need for early, accurate, and minimally invasive methods to detect and monitor cancer. Extracellular vesicles released by tumor cells carry molecular signatures such as proteins, RNA, and DNA that provide real-time information about tumor presence, progression, and response to treatment. Unlike traditional tissue biopsies, EV-based liquid biopsies allow for continuous monitoring through simple blood or body fluid samples, reducing patient discomfort and enabling earlier intervention.

The rising global cancer burden and increasing emphasis on personalized medicine have further driven the adoption of EV-based diagnostics in oncology. Additionally, these liquid biopsies help detect tumors that are difficult to access or monitor through conventional methods. Research and clinical trials continue to validate the efficacy of EV biomarkers in cancer detection, making this Sample Type the primary growth driver for the market. While other Sample Types like infectious diseases and neurological disorders are emerging, cancer diagnostics currently remain the focal point of EV-based liquid biopsy development and commercialization.

EV-Based Liquid Biopsy Market- Geographical Insights

In North America, the EV-based liquid biopsy market is experiencing strong momentum due to advanced healthcare infrastructure and early adoption of innovative diagnostic technologies. The region benefits from a robust research ecosystem supported by academic institutions, biotech companies, and government funding initiatives focused on cancer diagnostics. There is a growing awareness among healthcare professionals about the clinical value of extracellular vesicles in non-invasive disease detection and monitoring. The integration of EV-based tests into clinical practice is facilitated by the presence of well-established regulatory frameworks and ongoing clinical trials.

The United States is at the forefront of the EV-based liquid biopsy market, driven by its advanced healthcare infrastructure and strong emphasis on early cancer detection. The country's robust research ecosystem, encompassing leading academic institutions and bioEnd-user firms, fosters continuous innovation in diagnostic technologies. A growing preference for non-invasive diagnostic methods among clinicians and patients has accelerated the adoption of EV-based liquid biopsies, which offer real-time insights into disease progression and treatment response. The U.S. Food and Drug Administration (FDA) plays a pivotal role in regulating these emerging technologies, ensuring safety and efficacy standards are met. However, challenges persist, including the need for standardized protocols for EV isolation and analysis.

EV-Based Liquid Biopsy Market- Competitive Landscape:

The competitive landscape of the EV-based liquid biopsy market is shaped by a mix of established bioend-user firms and innovative startups focused on extracellular vesicle technologies. Companies such as Exosome Diagnostics, Thermo Fisher Scientific, and Qiagen are prominent players, leveraging their strong research capabilities and global reach to advance EV-based diagnostics. Bio-Techne Corporation and NanoView Biosciences are also making significant strides through technological innovations in EV detection and characterization. Meanwhile, System Biosciences (SBI), Miltenyi Biotec, and AMSBIO are contributing specialized EV isolation and analysis kits.

Emerging companies like Exosomics S.p.A, Codiak BioSciences, and VivaZome Therapeutics are intensifying competition by developing novel EV-based platforms tailored for oncology and personalized medicine. The market is highly dynamic, with strategic collaborations, research partnerships, and clinical validations playing a key role in shaping competitive positioning. As regulatory pathways become clearer, these companies are expected to expand their presence in clinical settings.

Recent Developments:

In October 2024, QIAGEN expanded its automated liquid biopsy portfolio to enhance oncology, prenatal care, and organ transplant applications. The new ccfDNA Kit upgrade with a urine protocol for EZ1 and 2 instruments is designed to improve liquid biopsy workflows for cancer research. The QIAsymphony DSP Circulating DNA and Maxi Kits deliver high-quality cfDNA for downstream applications.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL EV-BASED LIQUID BIOPSY MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Exosome Diagnostics
  • Bio-Techne Corporation
  • Thermo Fisher Scientific
  • NanoView Biosciences
  • System Biosciences (SBI)
  • Qiagen
  • Norgen Biotek Corp.
  • BioVision Inc.
  • Miltenyi Biotec
  • Creative Biolabs
  • AMSBIO
  • Exosomics S.p.A
  • NX Pharmagen
  • VivaZome Therapeutics
  • Aethlon Medical
  • Evox Therapeutics
  • Capricor Therapeutics
  • Codiak BioSciences
  • Anjarium Biosciences
  • HansaBioMed Life Sciences

GLOBAL EV-BASED LIQUID BIOPSY MARKET, BY BIOMARKER TYPE- MARKET ANALYSIS, 2019 - 2032

  • Proteins
  • RNA (miRNA, mRNA, etc.)
  • DNA
  • Lipids
  • Others

GLOBAL EV-BASED LIQUID BIOPSY MARKET, BY SAMPLE TYPE- MARKET ANALYSIS, 2019 - 2032

  • Blood
  • Urine
  • Saliva
  • Cerebrospinal Fluid
  • Others

GLOBAL EV-BASED LIQUID BIOPSY MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032

  • Cancer Diagnostics
  • Infectious Diseases
  • Neurological Disorders
  • Cardiovascular Diseases
  • Others

GLOBAL EV-BASED LIQUID BIOPSY MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

  • Hospitals & Clinics
  • Research Institutes
  • Diagnostic Laboratories
  • Biopharmaceutical Companies
  • Others

GLOBAL EV-BASED LIQUID BIOPSY MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. EV-Based Liquid Biopsy Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. EV-Based Liquid Biopsy Market Snippet by Biomarker Type
    • 2.1.2. EV-Based Liquid Biopsy Market Snippet by Sample Type
    • 2.1.3. EV-Based Liquid Biopsy Market Snippet by Application
    • 2.1.4. EV-Based Liquid Biopsy Market Snippet by End-user
    • 2.1.5. EV-Based Liquid Biopsy Market Snippet by Country
    • 2.1.6. EV-Based Liquid Biopsy Market Snippet by Region
  • 2.2. Competitive Insights

3. EV-Based Liquid Biopsy Key Market Trends

  • 3.1. EV-Based Liquid Biopsy Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. EV-Based Liquid Biopsy Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. EV-Based Liquid Biopsy Market Opportunities
  • 3.4. EV-Based Liquid Biopsy Market Future Trends

4. EV-Based Liquid Biopsy Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. EV-Based Liquid Biopsy Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. EV-Based Liquid Biopsy Market Landscape

  • 6.1. EV-Based Liquid Biopsy Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. EV-Based Liquid Biopsy Market - By Biomarker Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Biomarker Type, 2024 & 2032 (%)
    • 7.1.2. Proteins
    • 7.1.3. RNA (miRNA, mRNA, etc.)
    • 7.1.4. DNA
    • 7.1.5. Lipids
    • 7.1.6. Others

8. EV-Based Liquid Biopsy Market - By Sample Type

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Sample Type, 2024 & 2032 (%)
    • 8.1.2. Blood
    • 8.1.3. Urine
    • 8.1.4. Saliva
    • 8.1.5. Cerebrospinal Fluid
    • 8.1.6. Others

9. EV-Based Liquid Biopsy Market - By Application

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Application, 2024 & 2032 (%)
    • 9.1.2. Cancer Diagnostics
    • 9.1.3. Infectious Diseases
    • 9.1.4. Neurological Disorders
    • 9.1.5. Cardiovascular Diseases
    • 9.1.6. Others

10. EV-Based Liquid Biopsy Market - By End-user

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Sample Type, 2024 & 2032 (%)
    • 10.1.2. Hospitals & Clinics
    • 10.1.3. Research Institutes
    • 10.1.4. Diagnostic Laboratories
    • 10.1.5. Biopharmaceutical Companies
    • 10.1.6. Others

11. EV-Based Liquid Biopsy Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. EV-Based Liquid Biopsy Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. EV-Based Liquid Biopsy Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.3.9. UK
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.9.3. UK Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 11.3.9.4. UK Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 11.3.9.5. UK Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.9.6. UK Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.3.10. France
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.10.3. France Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 11.3.10.4. France Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 11.3.10.5. France Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.10.6. France Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.3.11. Italy
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.11.3. Italy Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 11.3.11.4. Italy Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 11.3.11.5. Italy Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.11.6. Italy Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.3.12. Spain
      • 11.3.12.1. Overview
      • 11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.12.3. Spain Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 11.3.12.4. Spain Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 11.3.12.5. Spain Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.12.6. Spain Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.3.13. The Netherlands
      • 11.3.13.1. Overview
      • 11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.13.3. The Netherlands Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 11.3.13.4. The Netherlands Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 11.3.13.5. The Netherlands Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.13.6. The Netherlands Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Overview
      • 11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.14.6. Sweden Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.3.15. Russia
      • 11.3.15.1. Overview
      • 11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.15.3. Russia Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 11.3.15.4. Russia Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 11.3.15.5. Russia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.15.6. Russia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.3.16. Poland
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.16.3. Poland Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 11.3.16.4. Poland Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 11.3.16.5. Poland Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.16.6. Poland Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.3.17. Rest of Europe
      • 11.3.17.1. Overview
      • 11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.17.3. Rest of the Europe Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 11.3.17.4. Rest of the Europe Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 11.3.17.5. Rest of the Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.17.6. Rest of the Europe Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. EV-Based Liquid Biopsy Key Manufacturers in Asia Pacific
    • 11.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.4.4. APAC Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
    • 11.4.5. APAC Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
    • 11.4.6. APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.4.7. APAC Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.4.8. China
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.8.3. China Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 11.4.8.4. China Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 11.4.8.5. China Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.8.6. China Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.4.9. India
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.9.3. India Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 11.4.9.4. India Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 11.4.9.5. India Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.9.6. India Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.4.13. Indonesia
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.13.3. Indonesia Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 11.4.13.4. Indonesia Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 11.4.13.5. Indonesia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.13.6. Indonesia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.4.14. Thailand
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.14.3. Thailand Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 11.4.14.4. Thailand Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 11.4.14.5. Thailand Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.14.6. Thailand Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 11.5. Latin America (LATAM)
    • 11.5.1. Overview
    • 11.5.2. EV-Based Liquid Biopsy Key Manufacturers in Latin America
    • 11.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.5.4. LATAM Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
    • 11.5.5. LATAM Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
    • 11.5.6. LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.5.7. LATAM Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 11.6. Middle East and Africa (MEA)
    • 11.6.1. Overview
    • 11.6.2. EV-Based Liquid Biopsy Key Manufacturers in Middle East and Africa
    • 11.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.6.4. MEA Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
    • 11.6.5. MEA Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
    • 11.6.6. MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.6.7. MEA Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- EV-Based Liquid Biopsy Industry

  • 12.1. Competitive Dashboard
    • 12.1.1. Competitive Benchmarking
    • 12.1.2. Competitive Positioning
  • 12.2. Company Profiles
    • 12.2.1. Exosome Diagnostics
    • 12.2.2. Bio-Techne Corporation
    • 12.2.3. Thermo Fisher Scientific
    • 12.2.4. NanoView Biosciences
    • 12.2.5. System Biosciences (SBI)
    • 12.2.6. Qiagen
    • 12.2.7. Norgen Biotek Corp.
    • 12.2.8. BioVision Inc.
    • 12.2.9. Miltenyi Biotec
    • 12.2.10. Creative Biolabs
    • 12.2.11. AMSBIO
    • 12.2.12. Exosomics S.p.A
    • 12.2.13. NX Pharmagen
    • 12.2.14. VivaZome Therapeutics
    • 12.2.15. Aethlon Medical
    • 12.2.16. Evox Therapeutics
    • 12.2.17. Capricor Therapeutics
    • 12.2.18. Codiak BioSciences
    • 12.2.19. Anjarium Biosciences
    • 12.2.20. HansaBioMed Life Sciences

13. 360 Degree AnalystView

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us